Expression and clinical significance of angiotensin II type 1 receptor in human hepatocellular carcinoma

Duan,Yun-Fei; Li,Xiao-Dong; Zhu,Feng; Zhang,Feng

doi:10.3892/etm.2013.1411

2014-February Volume 7 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-February Volume 7 Issue 2

Full Size Image

Article

Expression and clinical significance of angiotensin II type 1 receptor in human hepatocellular carcinoma

Authors:
- Yun-Fei Duan
- Xiao-Dong Li
- Feng Zhu
- Feng Zhang
View Affiliations / Copyright

Affiliations: Department of Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China
Pages: 323-328
|
Published online on: November 15, 2013

https://doi.org/10.3892/etm.2013.1411
Expand metrics +

Abstract

This study aimed to investigate the expression of angiotensin II type 1 receptor (AT-1R) mRNA and the AT-1R protein in human primary hepatocellular carcinoma (PHC), and to attempt to elucidate their association with pathological and clinical characteristics. Fresh tumor and normal liver tissues were obtained from 44 patients with PHC following hepatectomies. AT-1R mRNA levels were quantitatively analyzed by quantitative polymerase chain reaction (qPCR) while the protein levels were assessed by immunohistochemistry. The expression levels of AT-1R were observed in hepatocellular carcinoma tissues and normal liver tissues. The level of AT-1R protein expression in normal liver tissues was higher compared with that in PHC tissues (P=0.0033). The AT‑1R mRNA levels were higher in patients with negative hepatitis B virus surface antigen (HBsAg), normal α-fetoprotein (AFP) levels and high tumor differentiation, compared with those in patients with positive HBsAg (P=0.0005), upregulated AFP levels (P=0.0008) and poor tumor differentiation (P=0.0290). No significant correlation was identified between the expression levels of AT-1R mRNA and general characteristics such as gender, age, cirrhotic nodules, tumor size, tumor encapsulation, tumor number, carcinoma embolus, tumor metastasis or tumor recurrence. Downregulated levels of AT-1R mRNA and AT-1R protein may indicate a poor prognosis for patients with PHC.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Bruix J and Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell. 5:215–219. 2004. View Article : Google Scholar
4	Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar
5	Paul M, Poyan Mehr A and Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev. 86:747–803. 2006. View Article : Google Scholar : PubMed/NCBI
6	Wang CH, Li F and Takahashi N: The renin angiotensin system and the metabolic syndrome. Open Hypertens J. 3:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
7	Tahmasebi M, Barker S, Puddefoot JR and Vinson GP: Localisation of renin-angiotensin system (RAS) components in breast. Br J Cancer. 95:67–74. 2006. View Article : Google Scholar : PubMed/NCBI
8	Jethon A, Pula B, Piotrowska A, et al: Angiotensin II type 1 receptor (AT-1R) expression correlates with VEGF-A and VEGF-D expression in invasive ductal breast cancer. Pathol Oncol Res. 18:867–873. 2012. View Article : Google Scholar : PubMed/NCBI
9	Deshayes F and Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 16:293–299. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kobie JJ, Wu RS, Kurt RA, et al: Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63:1860–1864. 2003.PubMed/NCBI
11	Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al: Inflammation and angiotensin II. Int J Biochem Cell Biol. 35:881–900. 2003. View Article : Google Scholar
12	Tsutamoto T, Wada A, Maeda K, et al: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 35:714–721. 2000. View Article : Google Scholar
13	Kawamata H, Furihata T, Omotehara F, et al: Identification of genes differentially expressed in a newly isolated human metastasizing esophageal cancer cell line, T.Tn-AT1, by cDNA microarray. Cancer Sci. 94:699–706. 2003. View Article : Google Scholar
14	Wilop S, von Hobe S, Crysandt M, et al: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 135:1429–1435. 2009. View Article : Google Scholar
15	Huang W, Wu YL, Zhong J, et al: Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig Dis Sci. 53:1206–1210. 2008. View Article : Google Scholar : PubMed/NCBI
16	Huang W, Yu LF, Zhong J, et al: Angiotensin II type 1 receptor expression in human gastric cancer and induces MMP2 and MMP9 expression in MKN-28 cells. Dig Dis Sci. 53:163–168. 2008. View Article : Google Scholar : PubMed/NCBI
17	Inwang ER, Puddefoot JR, Brown CL, et al: Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer. 75:1279–1283. 1997. View Article : Google Scholar : PubMed/NCBI
18	Chen X, Meng Q, Zhao Y, et al: Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 328:318–324. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ino K, Shibata K, Kajiyama H, et al: Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 94:552–560. 2006. View Article : Google Scholar : PubMed/NCBI
20	Tanaka N, Miyajima A, Kosaka T, et al: Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer. Br J Cancer. 105:1331–1337. 2011. View Article : Google Scholar : PubMed/NCBI
21	Shirotake S, Miyajima A, Kosaka T, et al: Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology. 77:e19–25. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ohta T, Amaya K, Yi S, et al: Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol. 23:593–598. 2003.PubMed/NCBI
23	Gong Q, Davis M, Chipitsyna G, et al: Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas. 39:581–594. 2010. View Article : Google Scholar : PubMed/NCBI
24	Uemura H, Ishiguro H, Nakaigawa N, et al: Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2:1139–1147. 2003.
25	Guimond MO, Battista MC, Nikjouitavabi F, et al: Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer. Prostate. 73:1057–1068. 2013. View Article : Google Scholar : PubMed/NCBI
26	Hoshino K, Ishiguro H, Teranishi J, et al: Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate. 71:964–975. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kosaka T, Miyajima A, Shirotake S, et al: Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer. Prostate. 71:1510–1517. 2011.PubMed/NCBI
28	Di MJ, Wang WX, Lan MY, et al: Expression and significance of angiotensin II typeI receptor in human hepatocellular carcinoma. Medical Journal of Wuhan University. 26:235–237. 2005.(In Chinese).
29	Wu Y, Cahill PA and Sitzmann JV: Decreased angiotensin II receptors mediate decreased vascular response in hepatocellular cancer. Ann Surg. 223:225–231. 1996. View Article : Google Scholar : PubMed/NCBI
30	Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
31	Capece D, Fischietti M, Verzella D, et al: The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013:1872042013. View Article : Google Scholar : PubMed/NCBI
32	Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
33	Li XM, Tang ZY, Qin LX, et al: Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 18:511–517. 1999.PubMed/NCBI
34	Fujiyama S, Matsubara H, Nozawa Y, et al: Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res. 88:22–29. 2001. View Article : Google Scholar
35	Takeda H and Kondo S: Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol. 158:1633–1637. 2001. View Article : Google Scholar : PubMed/NCBI
36	De Paepe B, Verstraeten VL, De Potter CR, et al: Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol. 116:247–254. 2001.PubMed/NCBI